Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tyler William Snedden"'
Autor:
Anusha Vaidyanathan, Anna Taranova, Samina Qamar, Roberto Villarreal, Tyler William Snedden, Sukeshi Patel Arora, Andrew McCracken
Publikováno v:
JCO Oncol Pract
INTRODUCTION: In 2014, a reflexive screening protocol for Lynch syndrome (LS) via an immunohistochemistry (IHC) assay was shown to be cost-effective; however, the screening rates at a predominant Hispanic-rich institution are unclear. We hypothesized
Autor:
Kate Ida Lathrop, Ryan Williams, Kelly Pippin, James H. K. Yoo, Jean-Pierre Blaize, Brian Warnecke, Travis M. Cox, Christine Ann Moore, Lakene Raissa Djoufack Djoumessi, Flavia Fernandes, Madison H. Williams, Sushanth Kakarla, Michelle Janania Martinez, Juan Garza, Prathibha Surapaneni, Tyler William Snedden
Publikováno v:
Journal of Clinical Oncology. 38:e17059-e17059
e17059 Background: Hispanics (HI) are the fastest growing ethnic group in the US, representing 52% of US population growth from 2010-2018. In the past decade, they have also experienced a rise in incidence of testicular cancer. Studies have shown tha
Autor:
Adolfo Enrique Diaz Duque, Sushanth Kakarla, Tyler William Snedden, Prathibha Surapaneni, Jeremy Rawlings, David Gregorio, Snegha Ananth, Joel E. Michalek, Qianqian Liu, Michelle Janania Martinez, Juan Garza
Publikováno v:
Journal of Clinical Oncology. 38:e20083-e20083
e20083 Background: Non-Hodgkin Lymphoma (NHL) continues to be in the top 10 of all cancer related deaths. Discrepancies exist among world regions in lymphoma subtype incidence, with a percentage of DLBCL being higher in Latin America versus Nordic co
Autor:
Jeremy Rawlings, Adolfo Enrique Diaz Duque, Snegha Ananth, Dave Gregorio, Tyler William Snedden, Michelle Janania Martinez, Juan Garza, Sushanth Kakarla, Prathibha Surapaneni, Qianqian Liu, Joel E. Michalek
Publikováno v:
Journal of Clinical Oncology. 38:e20047-e20047
e20047 Background: Follicular Lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. It is most commonly diagnosed in non-Hispanics (NH) and is well characterized in this population. Hispanics (HI) on the other hand have been histori
Autor:
David Gregorio, Joel E. Michalek, Jeremy Rawlings, Prathibha Surapaneni, Snegha Ananth, Tyler William Snedden, Michelle Janania Martinez, Juan Garza, Qianqian Liu, Sushanth Kakarla, Adolfo E Diaz
Publikováno v:
Blood. 134:2141-2141
Introduction: Historically, a lack of health insurance has been reported to correlate with decreased access to medical care, a delay in cancer treatment and poorer outcomes overall. Furthermore, access to preventive services for cancer screening also
Autor:
Joel E. Michalek, Snegha Ananth, Sushanth Kakarla, Jeremy Rawlings, Qianqian Liu, David Gregorio, Adolfo E Diaz, Michelle Janania Martinez, Juan Garza, Tyler William Snedden, Prathibha Surapaneni
Publikováno v:
Blood. 134:4056-4056
BACKGROUND It is estimated that 8110 persons will be diagnosed with Hodgkin Lymphoma (HL) in the US during 2019, but the advent of new treatment options has increased the cure rate to at least 80%. It has been reported that the rates of HL are lower
Autor:
Michelle Janania Martinez, Juan Garza, Adolfo E Diaz, Daniela Hernandez, Tyler William Snedden
Publikováno v:
Blood. 134:2916-2916
BACKGROUND: Diffuse Large B Cell Lymphoma (DLBCL) is the most common hematologic malignancy in adults. Unfortunately, more than one-third of patients will fail first line therapy, highlighting the need for a better understanding of biology of DLBCL a
Autor:
Joel E. Michalek, Adolfo E Diaz, Michelle Janania Martinez, Prathibha Surapaneni, Juan Garza, Jeremy Rawlings, David Gregorio, Sushanth Kakarla, Qianqian Liu, Snegha Ananth, Tyler William Snedden
Publikováno v:
Blood. 134:2204-2204
BACKGROUND Evidence suggests that co-morbidities at diagnosis can influence treatment decisions and outcomes in lymphoma patients. Considering the bimodal presentation of Hodgkin Lymphoma (HL) and that the majority of Non-Hodgkin lymphoma (NHL) patie
Autor:
Andrew McCracken, Anna Taranova, Tyler William Snedden, Anusha Vaidyanathan, Sukeshi R. Patel, Roberto Villarreal, Carla McGruder
Publikováno v:
Journal of Clinical Oncology. 35:199-199
199 Background: Historically, the Amsterdam and Bethesda criteria were used to select patients (pts) for LS screening. In 2014, universal screening (US) for LS was shown to be cost effective. Thus, to increase LS screening, we implemented an algorith